Concurrent use of celecoxib and CYP2D6 substrates common

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1503, 2005-01, pp. : 20-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CYP2D6 metabolism determines drug use in psychiatric disorders

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 419, 2003-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Prevalence of CYP2D6-metabolised drug use varies

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 527, 2007-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment

By Walko Christine M   McLeod Howard  

Pharmacogenomics, Vol. 13, Iss. 6, 2012-04 ,pp. : 691-697

Future Medicine

Access to resources Recommend Favorite

Molecular Characterization of CYP2B6 Substrates

By  

Current Drug Metabolism, Vol. 9, Iss. 5, 2008-06 ,pp. : 363-373

Bentham Science Publishers

Access to resources Recommend Favorite

The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol

By Krauwinkel Walter   Dickinson James   Schaddelee Marloes   Meijer John   Tretter Reiner   Wetering Jeroen   Strabach Gregory   Gelderen Marcel  

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 39, Iss. 1, 2014-03 ,pp. : 43-52

Springer Publishing Company

Access to resources Recommend Favorite